Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.

Employees - 45, CEO - Amir Reichman, Sector - Healthcare, Country - IL, Market Cap -

Altman ZScore(max is 10): -11.49, Piotroski Score(max is 10): 2, Working Capital: $1255991, Total Assets: $17174876, Retained Earnings: $-124271105, EBIT: -8422161, Total Liabilities: $5442960, Revenue: $1493572

- Current Price $ - Analyst Target Price $